{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,13]],"date-time":"2026-06-13T03:08:24Z","timestamp":1781320104716,"version":"3.54.1"},"reference-count":69,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,8,4]],"date-time":"2021-08-04T00:00:00Z","timestamp":1628035200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004203","name":"Ontario Institute for Cancer Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004203","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010661","name":"Southeastern Ontario Academic Medical Organization","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010661","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jmdjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Molecular Diagnostics"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1016\/j.jmoldx.2021.07.010","type":"journal-article","created":{"date-parts":[[2021,8,5]],"date-time":"2021-08-05T12:05:45Z","timestamp":1628165145000},"page":"1292-1305","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Validation, Implementation, and Clinical Impact of the Oncomine Myeloid Targeted-Amplicon DNA and RNA Ion Semiconductor Sequencing Assay"],"prefix":"10.1016","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9309-2132","authenticated-orcid":false,"given":"Christina K.","family":"Ferrone","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0958-4781","authenticated-orcid":false,"given":"Henry","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Semenuk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5974-9479","authenticated-orcid":false,"given":"Barnaba","family":"Werunga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brooke","family":"Snetsinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grace","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janet","family":"Lui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillaume","family":"Richard-Carpentier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3702-5415","authenticated-orcid":false,"given":"Susan","family":"Crocker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2471-5775","authenticated-orcid":false,"given":"David","family":"Good","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4581-3390","authenticated-orcid":false,"given":"Annette E.","family":"Hay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Graeme","family":"Quest","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nancy","family":"Carson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1388-2183","authenticated-orcid":false,"given":"Harriet E.","family":"Feilotter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Rauh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jmoldx.2021.07.010_bib1","doi-asserted-by":"crossref","first-page":"759","DOI":"10.5858\/arpa.2016-0547-RA","article-title":"Integration of technical, bioinformatic, and variant assessment approaches in the validation of a targeted next-generation sequencing panel for myeloid malignancies","volume":"141","author":"Thomas","year":"2017","journal-title":"Arch Pathol Lab Med"},{"key":"10.1016\/j.jmoldx.2021.07.010_bib2","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1186\/1471-2407-12-304","article-title":"Myeloid malignancies: mutations, models and management","volume":"12","author":"Murati","year":"2012","journal-title":"BMC Cancer"},{"key":"10.1016\/j.jmoldx.2021.07.010_bib3","doi-asserted-by":"crossref","first-page":"3616","DOI":"10.1182\/blood-2013-08-518886","article-title":"Clinical and biological implications of driver mutations in myelodysplastic syndromes","volume":"122","author":"Papaemmanuil","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.jmoldx.2021.07.010_bib4","series-title":"Myelodysplastic syndromes and myeloproliferative disorders","author":"Hofmann","year":"2016"},{"key":"10.1016\/j.jmoldx.2021.07.010_bib5","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia","volume":"127","author":"Arber","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.jmoldx.2021.07.010_bib6","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/j.blre.2016.06.001","article-title":"The 2016 revision of WHO classification of myeloproliferative neoplasms: clinical and molecular advances","volume":"30","author":"Barbui","year":"2016","journal-title":"Blood Rev"},{"key":"10.1016\/j.jmoldx.2021.07.010_bib7","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1056\/NEJMoa1112304","article-title":"Prognostic relevance of integrated genetic profiling in acute myeloid leukemia","volume":"366","author":"Patel","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jmoldx.2021.07.010_bib8","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1056\/NEJMoa1516192","article-title":"Genomic classification and prognosis in acute myeloid leukemia","volume":"374","author":"Papaemmanuil","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jmoldx.2021.07.010_bib9","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1038\/leu.2013.336","article-title":"Landscape of genetic lesions in 944 patients with myelodysplastic syndromes","volume":"28","author":"Haferlach","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/j.jmoldx.2021.07.010_bib10","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1038\/leu.2015.337","article-title":"Age-related mutations and chronic myelomonocytic leukemia","volume":"30","author":"Mason","year":"2016","journal-title":"Leukemia"},{"key":"10.1016\/j.jmoldx.2021.07.010_bib11","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1038\/leu.2011.10","article-title":"Molecular profiling of chronic myelomonocytic leukemia reveals diverse mutations in >80% of patients with TET2 and EZH2 being of high prognostic relevance","volume":"25","author":"Grossmann","year":"2011","journal-title":"Leukemia"},{"key":"10.1016\/j.jmoldx.2021.07.010_bib12","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1136\/jmedgenet-2019-106152","article-title":"CCMG practice guideline: laboratory guidelines for next-generation sequencing","volume":"56","author":"Hume","year":"2019","journal-title":"J Med Genet"},{"key":"10.1016\/j.jmoldx.2021.07.010_bib13","doi-asserted-by":"crossref","first-page":"2482","DOI":"10.1182\/bloodadvances.2018024729","article-title":"Comorbid and inflammatory characteristics of genetic subtypes of clonal hematopoiesis","volume":"3","author":"Cook","year":"2019","journal-title":"Blood Adv"},{"key":"10.1016\/j.jmoldx.2021.07.010_bib14","doi-asserted-by":"crossref","first-page":"2745","DOI":"10.1200\/JCO.2015.66.2510","article-title":"Randomized phase II study of azacitidine alone or in combination with lenalidomide or with vorinostat in higher-risk myelodysplastic syndromes and chronic myelomonocytic leukemia: North American Intergroup Study SWOG S1117","volume":"35","author":"Sekeres","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jmoldx.2021.07.010_bib15","doi-asserted-by":"crossref","first-page":"D777","DOI":"10.1093\/nar\/gkw1121","article-title":"COSMIC: somatic cancer genetics at high-resolution","volume":"45","author":"Forbes","year":"2017","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.jmoldx.2021.07.010_bib16","doi-asserted-by":"crossref","first-page":"e31","DOI":"10.1158\/0008-5472.CAN-17-0337","article-title":"Variant review with the Integrative Genomics Viewer","volume":"77","author":"Robinson","year":"2017","journal-title":"Cancer Res"},{"key":"10.1016\/j.jmoldx.2021.07.010_bib17","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.jmoldx.2017.11.003","article-title":"Standards and guidelines for validating next-generation sequencing bioinformatics pipelines: a joint recommendation of the Association for Molecular Pathology and the College of American Pathologists","volume":"20","author":"Roy","year":"2018","journal-title":"J Mol Diagn"},{"key":"10.1016\/j.jmoldx.2021.07.010_bib18","doi-asserted-by":"crossref","first-page":"60","DOI":"10.6004\/jnccn.2017.0007","article-title":"Myelodysplastic syndromes, version 2.2017, NCCN clinical practice guidelines in oncology","volume":"15","author":"Greenberg","year":"2017","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.jmoldx.2021.07.010_bib19","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1053\/j.seminoncol.2016.10.003","article-title":"Genetic predisposition to leukemia and other hematologic malignancies","volume":"43","author":"Feurstein","year":"2016","journal-title":"Semin Oncol"},{"key":"10.1016\/j.jmoldx.2021.07.010_bib20","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1182\/blood-2016-05-670240","article-title":"How I diagnose and manage individuals at risk for inherited myeloid malignancies","volume":"128","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.jmoldx.2021.07.010_bib21","series-title":"WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues","author":"Swerdlow","year":"2017"},{"key":"10.1016\/j.jmoldx.2021.07.010_bib22","doi-asserted-by":"crossref","first-page":"2496","DOI":"10.1056\/NEJMoa1013343","article-title":"Clinical effect of point mutations in myelodysplastic syndromes","volume":"364","author":"Bejar","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jmoldx.2021.07.010_bib23","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1182\/blood.V126.23.907.907","article-title":"Somatic mutations in MDS patients are associated with clinical features and predict prognosis independent of the IPSS-R: analysis of combined datasets from the International Working Group for Prognosis in MDS-Molecular Committee","volume":"126","author":"Bejar","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.jmoldx.2021.07.010_bib24","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1080\/10428194.2020.1723013","article-title":"Wide variation in use and interpretation of gene mutation profiling panels among health care providers of patients with myelodysplastic syndromes (MDS): results of a large web-based survey","volume":"61","author":"Pine","year":"2020","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.jmoldx.2021.07.010_bib25","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1182\/bloodadvances.2018026989","article-title":"NPM1 mutations define a specific subgroup of MDS and MDS\/MPN patients with favorable outcomes with intensive chemotherapy","volume":"3","author":"Montalban-Bravo","year":"2019","journal-title":"Blood Adv"},{"key":"10.1016\/j.jmoldx.2021.07.010_bib26","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1056\/NEJMoa1716984","article-title":"Durable remissions with ivosidenib in IDH1-mutated relapsed or refractory AML","volume":"378","author":"DiNardo","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jmoldx.2021.07.010_bib27","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1182\/blood-2017-04-779405","article-title":"Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia","volume":"130","author":"Stein","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.jmoldx.2021.07.010_bib28","doi-asserted-by":"crossref","first-page":"e309","DOI":"10.1016\/S2352-3026(19)30284-4","article-title":"Enasidenib in patients with mutant IDH2 myelodysplastic syndromes: a phase 1 subgroup analysis of the multicentre, AG221-C-001 trial","volume":"7","author":"Stein","year":"2020","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.jmoldx.2021.07.010_bib29","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1182\/blood-2019-130501","article-title":"Preliminary results from the phase II study of the IDH2-inhibitor enasidenib in patients with high-risk IDH2-mutated myelodysplastic syndromes (MDS)","volume":"134","author":"Richard-Carpentier","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.jmoldx.2021.07.010_bib30","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1056\/NEJMoa1614359","article-title":"Midostaurin plus chemotherapy for acute myeloid leukemia with a FLT3 mutation","volume":"377","author":"Stone","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jmoldx.2021.07.010_bib31","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1056\/NEJMoa1908892","article-title":"Luspatercept in patients with lower-risk myelodysplastic syndromes","volume":"382","author":"Fenaux","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jmoldx.2021.07.010_bib32","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1182\/blood-2019-131055","article-title":"Phase 2 results of APR-246 and azacitidine (AZA) in patients with TP53 mutant myelodysplastic syndromes (MDS) and oligoblastic acute myeloid leukemia (AML)","volume":"134","author":"Sallman","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.jmoldx.2021.07.010_bib33","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1182\/blood-2019-125579","article-title":"APR-246 combined with azacitidine (AZA) in TP53 mutated myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML): a phase 2 study by the Groupe Francophone Des My\u00e9lodysplasies (GFM)","volume":"134","author":"Cluzeau","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.jmoldx.2021.07.010_bib34","doi-asserted-by":"crossref","first-page":"3371","DOI":"10.1182\/blood-2017-01-763425","article-title":"Clinical significance of somatic mutation in unexplained blood cytopenia","volume":"129","author":"Malcovati","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.jmoldx.2021.07.010_bib35","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.3324\/haematol.2019.222059","article-title":"Proposed diagnostic criteria for classical CMML, CMML variants and pre-CMML conditions","volume":"104","author":"Valent","year":"2019","journal-title":"Haematologica"},{"key":"10.1016\/j.jmoldx.2021.07.010_bib36","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1182\/blood-2016-08-733196","article-title":"Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel","volume":"129","author":"Dohner","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.jmoldx.2021.07.010_bib37","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1182\/bloodadvances.2018015875","article-title":"Targeted next-generation sequencing in blast phase myeloproliferative neoplasms","volume":"2","author":"Lasho","year":"2018","journal-title":"Blood Adv"},{"key":"10.1016\/j.jmoldx.2021.07.010_bib38","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1038\/leu.2017.139","article-title":"The role of LNK\/SH2B3 genetic alterations in myeloproliferative neoplasms and other hematological disorders","volume":"31","author":"Maslah","year":"2017","journal-title":"Leukemia"},{"key":"10.1016\/j.jmoldx.2021.07.010_bib39","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1038\/leu.2013.119","article-title":"Mutations and prognosis in primary myelofibrosis","volume":"27","author":"Vannucchi","year":"2013","journal-title":"Leukemia"},{"key":"10.1016\/j.jmoldx.2021.07.010_bib40","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.6004\/jnccn.2017.0157","article-title":"NCCN guidelines insights: myeloproliferative neoplasms, version 2.2018","volume":"15","author":"Mesa","year":"2017","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.jmoldx.2021.07.010_bib41","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1182\/bloodadvances.2016000216","article-title":"Targeted deep sequencing in polycythemia vera and essential thrombocythemia","volume":"1","author":"Tefferi","year":"2016","journal-title":"Blood Adv"},{"key":"10.1016\/j.jmoldx.2021.07.010_bib42","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1182\/blood-2017-02-734541","article-title":"Diagnosis and classification of hematologic malignancies on the basis of genetics","volume":"130","author":"Taylor","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.jmoldx.2021.07.010_bib43","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1182\/blood-2014-05-578435","article-title":"Clinical effect of driver mutations of JAK2, CALR, or MPL in primary myelofibrosis","volume":"124","author":"Rumi","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.jmoldx.2021.07.010_bib44","doi-asserted-by":"crossref","first-page":"e333","DOI":"10.1097\/HS9.0000000000000333","article-title":"Mutant calreticulin in myeloproliferative neoplasms","volume":"4","author":"Prins","year":"2020","journal-title":"HemaSphere"},{"key":"10.1016\/j.jmoldx.2021.07.010_bib45","first-page":"1","article-title":"Essential thrombocythemia treatment algorithm 2018","volume":"8","author":"Tefferi","year":"2018","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.jmoldx.2021.07.010_bib46","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1182\/blood-2015-05-646489","article-title":"Clinical and prognostic significance of 3q26.2 and other chromosome 3 abnormalities in CML in the era of tyrosine kinase inhibitors","volume":"126","author":"Wang","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.jmoldx.2021.07.010_bib47","doi-asserted-by":"crossref","first-page":"E320","DOI":"10.1002\/ajh.24378","article-title":"The different prognostic impact of type-1 or type-1 like and type-2 or type-2 like CALR mutations in patients with primary myelofibrosis","volume":"91","author":"Li","year":"2016","journal-title":"Am J Hematol"},{"key":"10.1016\/j.jmoldx.2021.07.010_bib48","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1200\/JCO.2017.76.4886","article-title":"MIPSS70: mutation-enhanced international prognostic score system for transplantation-age patients with primary myelofibrosis","volume":"36","author":"Guglielmelli","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jmoldx.2021.07.010_bib49","doi-asserted-by":"crossref","first-page":"E128","DOI":"10.1002\/ajh.25065","article-title":"Mayo CALR mutation type classification guide using alpha helix propensity","volume":"93","author":"Lasho","year":"2018","journal-title":"Am J Hematol"},{"key":"10.1016\/j.jmoldx.2021.07.010_bib50","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1182\/blood-2016-10-695973","article-title":"Myeloid neoplasms with eosinophilia","volume":"129","author":"Reiter","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.jmoldx.2021.07.010_bib51","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1182\/blood-2016-01-693879","article-title":"Spectrum and prognostic relevance of driver gene mutations in acute myeloid leukemia","volume":"128","author":"Metzeler","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.jmoldx.2021.07.010_bib52","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1038\/leu.2013.186","article-title":"The importance of relative mutant level for evaluating impact on outcome of KIT, FLT3 and CBL mutations in core-binding factor acute myeloid leukemia","volume":"27","author":"Allen","year":"2013","journal-title":"Leukemia"},{"key":"10.1016\/j.jmoldx.2021.07.010_bib53","doi-asserted-by":"crossref","first-page":"721","DOI":"10.6004\/jnccn.2019.0028","article-title":"Acute myeloid leukemia, version 3.2019, NCCN Clinical Practice Guidelines in Oncology","volume":"17","author":"Tallman","year":"2019","journal-title":"J Natl Compr Cancer Netw"},{"key":"10.1016\/j.jmoldx.2021.07.010_bib54","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1182\/blood-2019-01-894980","article-title":"Management of acute promyelocytic leukemia: updated recommendations from an expert panel of the European LeukemiaNet","volume":"133","author":"Sanz","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.jmoldx.2021.07.010_bib55","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.jmoldx.2016.10.002","article-title":"Standards and guidelines for the interpretation and reporting of sequence variants in cancer: a joint consensus recommendation of the Association for Molecular Pathology, American Society of Clinical Oncology, and College of American Pathologists","volume":"19","author":"Li","year":"2017","journal-title":"J Mol Diagn"},{"key":"10.1016\/j.jmoldx.2021.07.010_bib56","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.jmoldx.2017.01.011","article-title":"Guidelines for validation of next-generation sequencing\u2013based oncology panels: a joint consensus recommendation of the Association for Molecular Pathology and College of American Pathologists","volume":"19","author":"Jennings","year":"2017","journal-title":"J Mol Diagn"},{"key":"10.1016\/j.jmoldx.2021.07.010_bib57","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1038\/gim.2013.92","article-title":"ACMG clinical laboratory standards for next-generation sequencing","volume":"15","author":"Rehm","year":"2013","journal-title":"Genet Med"},{"key":"10.1016\/j.jmoldx.2021.07.010_bib58","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1038\/nbt.2403","article-title":"Assuring the quality of next-generation sequencing in clinical laboratory practice","volume":"30","author":"Gargis","year":"2012","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.jmoldx.2021.07.010_bib59","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1586\/14737159.2016.1142374","article-title":"Principles of analytical validation of next-generation sequencing based mutational analysis for hematologic neoplasms in a CLIA-certified laboratory","volume":"16","author":"Kanagal-Shamanna","year":"2016","journal-title":"Expert Rev Mol Diagn"},{"key":"10.1016\/j.jmoldx.2021.07.010_bib60","series-title":"Medical Laboratory Accreditation Requirements: Version 7. Toronto, ON: Institute for Quality Management in Healthcare: Institute for Quality Management in Healthcare (IQMH)","year":"2016"},{"key":"10.1016\/j.jmoldx.2021.07.010_bib61","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/2041-2223-5-9","article-title":"Validation of high throughput sequencing and microbial forensics applications","volume":"5","author":"Budowle","year":"2014","journal-title":"Investig Genet"},{"key":"10.1016\/j.jmoldx.2021.07.010_bib62","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.jmoldx.2019.10.002","article-title":"Clinical validation of a myeloid next-generation sequencing panel for single-nucleotide variants, insertions\/deletions, and fusion genes","volume":"22","author":"Izevbaye","year":"2020","journal-title":"J Mol Diagn"},{"key":"10.1016\/j.jmoldx.2021.07.010_bib63","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.cancergen.2017.04.060","article-title":"The accurate detection by next-generation sequencing (NGS) of difficult to sequence genes (CALR, CEBPA, FLT3) associated with myeloid disorders using a hybridisation-based enrichment approach","volume":"214\u2013215","author":"Speight","year":"2017","journal-title":"Cancer Genet"},{"key":"10.1016\/j.jmoldx.2021.07.010_bib64","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1038\/nature13038","article-title":"Identification of pre-leukaemic haematopoietic stem cells in acute leukaemia","volume":"506","author":"Shlush","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.jmoldx.2021.07.010_bib65","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1182\/blood-2015-03-631747","article-title":"Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes","volume":"126","author":"Steensma","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.jmoldx.2021.07.010_bib66","doi-asserted-by":"crossref","first-page":"2488","DOI":"10.1056\/NEJMoa1408617","article-title":"Age-related clonal hematopoiesis associated with adverse outcomes","volume":"371","author":"Jaiswal","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jmoldx.2021.07.010_bib67","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1111\/ejh.13272","article-title":"Implementation of an NGS-based sequencing and gene fusion panel for clinical screening of patients with suspected hematologic malignancies","volume":"103","author":"Levy","year":"2019","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.jmoldx.2021.07.010_bib68","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1007\/s40291-020-00484-5","article-title":"Analytical and potential clinical performance of oncomine myeloid research assay for myeloid neoplasms","volume":"24","author":"Park","year":"2020","journal-title":"Mol Diagn Ther"},{"key":"10.1016\/j.jmoldx.2021.07.010_bib69","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1038\/s41375-020-0997-4","article-title":"Prognostic significance of serial molecular annotation in myelodysplastic syndromes (MDS) and secondary acute myeloid leukemia (sAML)","volume":"35","author":"Yun","year":"2020","journal-title":"Leukemia"}],"container-title":["The Journal of Molecular Diagnostics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525157821002348?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525157821002348?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T18:16:31Z","timestamp":1761502591000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525157821002348"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10]]},"references-count":69,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2021,10]]}},"alternative-id":["S1525157821002348"],"URL":"https:\/\/doi.org\/10.1016\/j.jmoldx.2021.07.010","relation":{},"ISSN":["1525-1578"],"issn-type":[{"value":"1525-1578","type":"print"}],"subject":[],"published":{"date-parts":[[2021,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Validation, Implementation, and Clinical Impact of the Oncomine Myeloid Targeted-Amplicon DNA and RNA Ion Semiconductor Sequencing Assay","name":"articletitle","label":"Article Title"},{"value":"The Journal of Molecular Diagnostics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jmoldx.2021.07.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Association for Molecular Pathology and American Society for Investigative Pathology. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}